MMMineyuki Mizuguchi

Mineyuki Mizuguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mineyuki Mizuguchi has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enthalpy-Informed Design of Dasatinib-Derived Small-Molecule Inhibitors of Transthyretin Amyloidogenesis

    by Takeshi Yokoyama, Airi Fukugawa, Ryoka Waki, Katsuhiro Kusaka, Haruki Sugiyama, Yuko Nabeshima, Mineyuki Mizuguchi, Takuya Okada, Naoki Toyooka

    Transthyretin (TTR) amyloidosis is driven by dissociation of the native tetramer into aggregation-prone monomers, making kinetic stabilization of the tetramer an established therapeutic strategy. Here, we demonstrate that binding enthalpy-guided optimization provides an effective strategy for developing selective TTR stabilizers. Starting from a kinase inhibitor-derived scaffold, stepwise optimization comprising scaffold simplification, terminal phenyl modification, and halogen substitution yielded compound 29, which exhibits aggregation inhibitory activity comparable to tafamidis and close to that of acoramidis. Isothermal titration calorimetry revealed that optimization predominantly improved binding enthalpy, while changes in binding free energy were modest. Combined X-ray and neutron crystallographic analyses suggested that the favorable enthalpy originates from enhanced shape complementarity and weak interactions rather than conventional hydrogen bonds. Importantly, compound 29 maintains robust binding to TTR in human plasma. These findings demonstrate that binding enthalpy can serve as a practical parameter for optimizing TTR amyloid inhibitors.

  • Open Access

    The stress-activated kinase p38 mediates non-canonical activation of Src and tyrosine phosphorylation of the adapter protein TAB1

    by Iimi Onuma, Yusuke Iwata, Yue Zhou, Mai Nakada, Arisa Kondo, Hiroyuki Iwahara, Kanako Natori, Satoru Yokoyama, Kazuyasu Chihara, Kenji Takeuchi, et al.

  • Catalytic Photooxygenation Demonstrates Therapeutic Efficacy in Transthyretin Amyloidosis

    by Mina Yamane, Hiroki Umeda, Moe Toyobe, Atsushi Iwai, Kuraudo Ishihara, Genki Kudo, Harunobu Mitsunuma, Yukiko Hori, Taisuke Tomita, Mineyuki Mizuguchi, et al.

    The escalating global trend of aging populations has brought attention to the rising prevalence of late-onset amyloid disorders. Among them, amyloid transthyretin (ATTR) amyloidosis presents a growing area of unmet medical needs. While current treatment modalities have demonstrated efficacy in preventing or delaying amyloid generation, methodology to selectively modify and neutralize existing amyloid burdens remains inadequately addressed, leaving the fundamental irreversibility and hence the fatality of these conditions, a long-standing medical challenge. Here, we report the first demonstration of therapeutic efficacy in ATTR amyloidosis via dynamic control of ATTR aggregation and toxicity, enabled by small-molecule organophotocatalysis. Selective incorporation of hydrophilic oxygen atoms into the hydrophobic amyloid core reshapes the aggregation landscape, neutralizing proteotoxicity, and mitigating cellular damage. Additionally, this targeted covalent modification significantly reduces in vivo ROS levels, correlating with the observed therapeutic effects in Caenorhabditis elegans, the only experimental model replicating key clinical manifestations of the disease. Docking simulations elucidated the molecular basis of catalyst performance, providing the foundational blueprint for amyloid-neutralizing organophotocatalysis. Collectively, this study provides a scalable approach to overcoming a persistent barrier in amyloidosis therapy.


  • Repurposing of Agrochemicals as ATTRv Amyloidosis Inhibitors

    by Takeshi Yokoyama, Satoru Fujiwara, Kai Nishikubo, Mineyuki Mizuguchi, Yuko Nabeshima, Naoki Toyooka, Takuya Okada, Yusuke Nakagawa

    Transthyretin (TTR), a plasma protein, undergoes transformation into amyloid fibers, leading to ATTRv amyloidosis, a disease characterized by organ deposition of TTR amyloid fibrils and subsequent organ failure. Developing compounds that bind and kinetically stabilize TTR is a crucial strategy in the treatment of ATTRv amyloidosis. In this study, we narrowed 651 pesticide-related compounds down to 14 possible TTR binders through in silico screening; subsequent in vitro analysis revealed that 7 of them exhibited amyloid fibril formation inhibition activity. The herbicide components bromoxynil (6) and ioxynil (21) showed especially high ligand efficiency and efficiently inhibited amyloid fibril formation of amyloidogenic V30M-TTR. Additionally, aclonifen (9) exhibited moderate fibril formation inhibition activity, but showed selective binding to TTR comparable to that of tafamidis. While improvement is needed to the selective TTR-binding or fibril formation inhibition activity, the compounds identified herein are promising lead candidates for the development of ATTRv amyloidosis therapeutics.


  • Open Access

    Divergent Total Synthesis of Isoflavone Natural Products and Their Potential as Therapeutic Agents for TTR Amyloidosis

    by Nguyen Ngoc Thanh Luan, Takuya Okada, Takeshi Yokoyama, Mie Suzuki, Yuko Nabeshima, Mineyuki Mizuguchi, Naoki Toyooka

    We have achieved the divergent total synthesis of nine isoflavone natural products 1-9 starting from commercially available 2,4,6-trihydroxyacetophenone as a starting material. The isoflavone skeleton of 1-9 was constructed by the Suzuki-Miyaura coupling reaction as the key reaction. Investigation of the potential of 1-9 as therapeutic agents for transthyretin (TTR) amyloidosis revealed that millexatin F (3) showed the best efficacy in ex vivo competitive binding experiments and thioflavin-T fluorescence studies. Therefore, millexatin F (3) is promising as a seed compound for a novel TTR amyloidosis therapeutic agent.


  • Structural insights into rapamycin‐induced oligomerization of a FRB–FKBP fusion protein

    by Tomonao Inobe, Runa Sakaguchi, Takayuki Obita, Atushi Mukaiyama, Seiichi Koike, Takeshi Yokoyama, Mineyuki Mizuguchi, Shuji Akiyama

    Inducible dimerization systems, such as rapamycin‐induced dimerization of FK506 binding protein (FKBP) and FKBP–rapamycin binding (FRB) domain, are widely employed chemical biology tools to manipulate cellular functions. We previously advanced an inducible dimerization system into an inducible oligomerization system by developing a bivalent fusion protein, FRB–FKBP, which forms large oligomers upon rapamycin addition and can be used to manipulate cells. However, the oligomeric structure of FRB–FKBP remains unclear. Here, we report that FRB–FKBP forms a rotationally symmetric trimer in crystals, but a larger oligomer in solution, primarily tetramers and pentamers, which maintain similar inter‐subunit contacts as in the crystal trimer. These findings expand the applications of the FRB–FKBP oligomerization system in diverse biological events.


  • SIRT5 mutants reveal the role of conserved asparagine and glutamine residues in the NAD+‐binding pocket

    by Takeshi Yokoyama, Yuki Takayama, Mineyuki Mizuguchi, Yuko Nabeshima, Katsuhiro Kusaka

    SIRT5, one of the mammalian sirtuins, specifically recognizes succinyl‐lysine residues on proteins and catalyzes the desuccinylation reaction. In this study, we characterized SIRT5 mutants with hydrophobic amino acid substitutions at Q140 and N141, in addition to the catalytic residue H158, known as an active site residue, by the Michaelis–Menten analysis and X‐ray crystallography. Kinetic analysis showed that the catalytic efficiency (kcat/Km) of the Q140L and N141V mutants decreased to 0.02 times and 0.0038 times that of the wild‐type SIRT5, respectively, with the activity of the N141V mutant becoming comparable to that of the H158M mutant. Our findings indicate that N141 contributes significantly to the desuccinylation reaction.


  • Open Access

    Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma

    by Mineyuki Mizuguchi, Yusuke Nakagawa, Takeshi Yokoyama, Takuya Okada, Kanako Fujii, Kanoko Takahashi, Nguyen Ngoc Thanh Luan, Yuko Nabeshima, Kayoko Kanamitsu, Shinsaku Nakagawa, et al.

    Transthyretin amyloidosis is a fatal disorder caused by transthyretin amyloid aggregation. Stabilizing the native structure of transthyretin is an effective approach to inhibit amyloid aggregation. To develop kinetic stabilizers of transthyretin, it is crucial to explore compounds that selectively bind to transthyretin in plasma. Our recent findings demonstrated that the uricosuric agent benziodarone selectively binds to transthyretin in plasma. Here, we report the development of benziodarone analogues with enhanced potency for selective binding to transthyretin in plasma compared to benziodarone. These analogues featured substituents of chlorine, bromine, iodine, a methyl group, or a trifluoromethyl group, at the 4-position of the benzofuran ring. X-ray crystal structure analysis revealed that CH···O hydrogen bonds and a halogen bond are important for the binding of the compounds to the thyroxine-binding sites. The bioavailability of benziodarone analogues with 4-Br, 4-Cl, or 4-CH3 was comparable to that of tafamidis, a current therapeutic agent for transthyretin amyloidosis.


  • Open Access

    Small molecule amyloid disrupters demonstrate therapeutic efficacy for transthyretin amyloidosis

    by Mina Yamane, Hiroki Umeda, Moe Toyobe, Atsushi Iwai, Genki Kudo, Harunobu Mitsunuma, Yukiko Hori, Taisuke Tomita, Mineyuki Mizuguchi, Masamitsu Okada, et al.

    The escalating global trend of an aging population has brought attention to the rising prevalence of late-onset amyloid disorders. Among them, transthyretin amyloidosis (ATTR) presents a growing medical challenge, particularly in the elderly. Herein we report the first therapeutic efficacy of a small molecule catalyst that selectively disrupts and neutralizes the intrinsic toxicity of aggregated transthyretin via photooxygenation. The established conditions demonstrated improved motility defect severity within the ATTR model C. elegans, the singularly acknowledged experimental modality recapitulating the clinical manifestation of ATTR. The approach was applicable to photooxygenation of cardiac amyloid fibrils extracted from an ATTR patient. In silico analysis provided a molecular rationale for the reactivity performance of the optimized catalyst, key to bridging the gap between in vivo applicability and therapeutic efficacy.